NLNK News and Press, NewLink Genetics From 02/01/19

NEW YORK, Feb. 01, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Marathon Oil Corporation (NYSE:MRO), Accuray Incorporated (NASDAQ:ARAY...

AMES, Iowa, Jan. 30, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the Company’s Chairman, CEO and Chief Scientific Officer, Charles J. Link, Jr, MD, will participate in the Immuno-Oncology 360 ° Conference (IO360 ° ...

Updated Phase 1 data for indoximod plus standard-of-care chemotherapy in newly diagnosed AML show post-induction minimal residual disease (MRD) negativity rate of 86% and post-consolidation MRD negativity of 100% Safety data from this study indicate the combination treatment regimen...

AMES, Iowa, Nov. 06, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that the following abstracts have been published and are now available on the Society for Immunotherapy of Cancer (SITC) Conference 2018 website. Abstracts for poster present...

NEW YORK, Nov. 06, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mercury Systems Inc (NASDAQ:MRCY), Lincoln Electric Holdings, Inc. (NASDA...

AMES, Iowa, Nov. 02, 2018 (GLOBE NEWSWIRE) -- In a release issued under the same headline yesterday by NewLink Genetics Corporation (NASDAQ:NLNK), the balance statement included in the press release was incorrect. The corrected release follows: NewLink Genetics Corporation (NASDAQ:NLN...

NewLink Genetics Corp (NLNK) Q3 2018 Earnings Conference Call November 1, 2018, 16:30 ET Executives Lisa Miller - Director, IR Charles Link - Co-Founder, Chairman, CEO & Chief Scientific Officer Eugene Kennedy - Chief Medical Officer Carl Langren - CFO & Principal Accou...

NewLink Genetics (NASDAQ: NLNK ): Q3 GAAP EPS of -$0.20 beats by $0.20 . Revenue of $0.12M (-97.8% Y/Y) misses by $2.05M . Press Release More news on: NewLink Genetics Corporation, Earnings news and commentary, Healthcare stocks news, ,

AMES, Iowa, Nov. 01, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported consolidated financial results for the third quarter 2018 and reviewed recent highlights and upcoming milestones. “NewLink Genetics continues to produce encouraging data sup...

AMES, Iowa, Nov. 01, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that an abstract with data pertaining to the use of the Company's investigational immuno-oncology molecule, indoximod, in combination therapy for patients with newly diagnosed acute ...